Impaired  ||| S:0 E:9 ||| NNP
FEF25-75  ||| S:9 E:18 ||| NNP
values  ||| S:18 E:25 ||| NNS
may  ||| S:25 E:29 ||| MD
predict  ||| S:29 E:37 ||| VB
bronchial  ||| S:37 E:47 ||| JJ
reversibility  ||| S:47 E:61 ||| NN
in  ||| S:61 E:64 ||| IN
allergic  ||| S:64 E:73 ||| JJ
children  ||| S:73 E:82 ||| NNS
with  ||| S:82 E:87 ||| IN
rhinitis  ||| S:87 E:96 ||| NN
or  ||| S:96 E:99 ||| CC
asthma  ||| S:99 E:106 ||| JJ
FEV1  ||| S:106 E:111 ||| NN
is  ||| S:111 E:114 ||| VBZ
considered  ||| S:114 E:125 ||| VBN
an  ||| S:125 E:128 ||| DT
important  ||| S:128 E:138 ||| JJ
parameter  ||| S:138 E:148 ||| NN
for  ||| S:148 E:152 ||| IN
asthma  ||| S:152 E:159 ||| JJ
diagnosis  ||| S:159 E:169 ||| NN
and  ||| S:169 E:173 ||| CC
follow-up ||| S:173 E:182 ||| JJ
.  ||| S:182 E:184 ||| .
However ||| S:184 E:191 ||| RB
,  ||| S:191 E:193 ||| ,
it  ||| S:193 E:196 ||| PRP
has  ||| S:196 E:200 ||| VBZ
been  ||| S:200 E:205 ||| VBN
proposed  ||| S:205 E:214 ||| VBN
that  ||| S:214 E:219 ||| IN
FEF25-75  ||| S:219 E:228 ||| NNP
could  ||| S:228 E:234 ||| MD
be  ||| S:234 E:237 ||| VB
more  ||| S:237 E:242 ||| RBR
sensitive  ||| S:242 E:252 ||| JJ
than  ||| S:252 E:257 ||| IN
FEV1  ||| S:257 E:262 ||| CD
to  ||| S:262 E:265 ||| TO
detect  ||| S:265 E:272 ||| VB
slight  ||| S:272 E:279 ||| JJ
airways  ||| S:279 E:287 ||| JJ
obstruction ||| S:287 E:298 ||| NN
.  ||| S:298 E:300 ||| .
Bronchial  ||| S:300 E:310 ||| NNP
reversibility  ||| S:310 E:324 ||| VBD
defined  ||| S:324 E:332 ||| VBN
by  ||| S:332 E:335 ||| IN
positive  ||| S:335 E:344 ||| JJ
response  ||| S:344 E:353 ||| NN
to  ||| S:353 E:356 ||| TO
bronchodilation  ||| S:356 E:372 ||| VB
test ||| S:372 E:376 ||| NN
.  ||| S:376 E:378 ||| .
The  ||| S:378 E:382 ||| DT
aim  ||| S:382 E:386 ||| NN
of  ||| S:386 E:389 ||| IN
the  ||| S:389 E:393 ||| DT
present  ||| S:393 E:401 ||| JJ
study  ||| S:401 E:407 ||| NN
was  ||| S:407 E:411 ||| VBD
to  ||| S:411 E:414 ||| TO
define  ||| S:414 E:421 ||| VB
whether  ||| S:421 E:429 ||| IN
an  ||| S:429 E:432 ||| DT
impaired  ||| S:432 E:441 ||| JJ
FEF25-75  ||| S:441 E:450 ||| CD
value  ||| S:450 E:456 ||| NN
( ||| S:456 E:457 ||| -LRB-
less  ||| S:457 E:462 ||| JJR
than  ||| S:462 E:467 ||| IN
65  ||| S:467 E:470 ||| CD
percent  ||| S:470 E:478 ||| NN
of  ||| S:478 E:481 ||| IN
predicted ||| S:481 E:490 ||| CD
)  ||| S:490 E:492 ||| -RRB-
may  ||| S:492 E:496 ||| MD
be  ||| S:496 E:499 ||| VB
predictive  ||| S:499 E:510 ||| VBN
for  ||| S:510 E:514 ||| IN
reversibility  ||| S:514 E:528 ||| NN
in  ||| S:528 E:531 ||| IN
a  ||| S:531 E:533 ||| DT
large  ||| S:533 E:539 ||| JJ
cohort  ||| S:539 E:546 ||| NN
of  ||| S:546 E:549 ||| IN
allergic  ||| S:549 E:558 ||| JJ
children  ||| S:558 E:567 ||| NNS
with  ||| S:567 E:572 ||| IN
rhinitis  ||| S:572 E:581 ||| NN
or  ||| S:581 E:584 ||| CC
asthma ||| S:584 E:590 ||| NN
.  ||| S:590 E:592 ||| .
Six  ||| S:592 E:596 ||| CD
hundred  ||| S:596 E:604 ||| CD
allergic  ||| S:604 E:613 ||| CD
children  ||| S:613 E:622 ||| NNS
were  ||| S:622 E:627 ||| VBD
recruited ||| S:627 E:636 ||| VBN
:  ||| S:636 E:638 ||| :
300  ||| S:638 E:642 ||| CD
with  ||| S:642 E:647 ||| IN
controlled  ||| S:647 E:658 ||| JJ
asthma  ||| S:658 E:665 ||| NN
and  ||| S:665 E:669 ||| CC
300  ||| S:669 E:673 ||| CD
with  ||| S:673 E:678 ||| IN
allergic  ||| S:678 E:687 ||| JJ
rhinitis ||| S:687 E:695 ||| NN
.  ||| S:695 E:697 ||| .
All  ||| S:697 E:701 ||| DT
of  ||| S:701 E:704 ||| IN
them  ||| S:704 E:709 ||| PRP
were  ||| S:709 E:714 ||| VBD
evaluated  ||| S:714 E:724 ||| VBN
by  ||| S:724 E:727 ||| IN
performing  ||| S:727 E:738 ||| VBG
spirometry ||| S:738 E:748 ||| NN
,  ||| S:748 E:750 ||| ,
bronchodilation  ||| S:750 E:766 ||| JJ
test ||| S:766 E:770 ||| NN
,  ||| S:770 E:772 ||| ,
and  ||| S:772 E:776 ||| CC
skin  ||| S:776 E:781 ||| NN
prick  ||| S:781 E:787 ||| NN
test ||| S:787 E:791 ||| NN
.  ||| S:791 E:793 ||| .
Two  ||| S:793 E:797 ||| CD
predictors  ||| S:797 E:808 ||| NNS
were  ||| S:808 E:813 ||| VBD
significantly  ||| S:813 E:827 ||| RB
associated  ||| S:827 E:838 ||| VBN
with  ||| S:838 E:843 ||| IN
bronchial  ||| S:843 E:853 ||| JJ
reversibility ||| S:853 E:866 ||| NN
:  ||| S:866 E:868 ||| :
i ||| S:868 E:869 ||| FW
)  ||| S:869 E:871 ||| -RRB-
an  ||| S:871 E:874 ||| DT
impaired  ||| S:874 E:883 ||| JJ
FEF25-75  ||| S:883 E:892 ||| CD
value  ||| S:892 E:898 ||| NN
( ||| S:898 E:899 ||| -LRB-
less  ||| S:899 E:904 ||| JJR
than  ||| S:904 E:909 ||| IN
65  ||| S:909 E:912 ||| CD
percent  ||| S:912 E:920 ||| NN
of  ||| S:920 E:923 ||| IN
predicted ||| S:923 E:932 ||| CD
) ||| S:932 E:933 ||| -RRB-
,  ||| S:933 E:935 ||| ,
and  ||| S:935 E:939 ||| CC
ii ||| S:939 E:941 ||| CD
)  ||| S:941 E:943 ||| -RRB-
sensitization  ||| S:943 E:957 ||| NN
to  ||| S:957 E:960 ||| TO
perennial  ||| S:960 E:970 ||| JJ
allergens ||| S:970 E:979 ||| NN
.  ||| S:979 E:981 ||| .
It  ||| S:981 E:984 ||| PRP
was  ||| S:984 E:988 ||| VBD
more  ||| S:988 E:993 ||| RBR
relevant  ||| S:993 E:1002 ||| JJ
in  ||| S:1002 E:1005 ||| IN
children  ||| S:1005 E:1014 ||| NNS
with  ||| S:1014 E:1019 ||| IN
rhinitis  ||| S:1019 E:1028 ||| NNS
( ||| S:1028 E:1029 ||| -LRB-
ORAdj ||| S:1029 E:1034 ||| NNP
: ||| S:1034 E:1035 ||| :
8.9  ||| S:1035 E:1039 ||| CD
and  ||| S:1039 E:1043 ||| CC
2.2  ||| S:1043 E:1047 ||| CD
respectively ||| S:1047 E:1059 ||| CD
) ||| S:1059 E:1060 ||| -RRB-
.  ||| S:1060 E:1062 ||| .
In  ||| S:1062 E:1065 ||| IN
conclusion ||| S:1065 E:1075 ||| NN
,  ||| S:1075 E:1077 ||| ,
this  ||| S:1077 E:1082 ||| DT
study ||| S:1082 E:1087 ||| NN
,  ||| S:1087 E:1089 ||| ,
conducted  ||| S:1089 E:1099 ||| VBN
in  ||| S:1099 E:1102 ||| IN
real  ||| S:1102 E:1107 ||| JJ
life ||| S:1107 E:1111 ||| NN
,  ||| S:1111 E:1113 ||| ,
could  ||| S:1113 E:1119 ||| MD
suggest  ||| S:1119 E:1127 ||| VB
that  ||| S:1127 E:1132 ||| IN
an  ||| S:1132 E:1135 ||| DT
impaired  ||| S:1135 E:1144 ||| JJ
FEF25-75  ||| S:1144 E:1153 ||| CD
value  ||| S:1153 E:1159 ||| NN
( ||| S:1159 E:1160 ||| -LRB-
less  ||| S:1160 E:1165 ||| JJR
than  ||| S:1165 E:1170 ||| IN
65  ||| S:1170 E:1173 ||| CD
percent  ||| S:1173 E:1181 ||| NN
of  ||| S:1181 E:1184 ||| IN
predicted ||| S:1184 E:1193 ||| CD
)  ||| S:1193 E:1195 ||| -RRB-
may  ||| S:1195 E:1199 ||| MD
be  ||| S:1199 E:1202 ||| VB
considered  ||| S:1202 E:1213 ||| VBN
a  ||| S:1213 E:1215 ||| DT
reliable  ||| S:1215 E:1224 ||| JJ
marker  ||| S:1224 E:1231 ||| NN
of  ||| S:1231 E:1234 ||| IN
bronchial  ||| S:1234 E:1244 ||| JJ
reversibility ||| S:1244 E:1257 ||| NN
,  ||| S:1257 E:1259 ||| ,
mainly  ||| S:1259 E:1266 ||| RB
in  ||| S:1266 E:1269 ||| IN
children  ||| S:1269 E:1278 ||| NNS
with  ||| S:1278 E:1283 ||| IN
allergic  ||| S:1283 E:1292 ||| JJ
rhinitis ||| S:1292 E:1300 ||| NN
.  ||| S:1300 E:1302 ||| .
